Back

Yikes! Fair skepticism—biotech IPOs can be brutal for retail investors. Molbio’s timing is definitely interesting, but I think the underlying tech has real potential beyond the COVID spike. That said, the company wouldn’t be at this stage without the pandemic-driven demand. I’m curious to see if they can scale like Cepheid or if this is just a well-timed cash-out. Would a post-IPO correction change your mind, or are you completely out on biotech?